Lawrence H. Einhorn

40.7k total citations · 7 hit papers
548 papers, 27.3k citations indexed

About

Lawrence H. Einhorn is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lawrence H. Einhorn has authored 548 papers receiving a total of 27.3k indexed citations (citations by other indexed papers that have themselves been cited), including 369 papers in Surgery, 185 papers in Pulmonary and Respiratory Medicine and 143 papers in Oncology. Recurrent topics in Lawrence H. Einhorn's work include Testicular diseases and treatments (330 papers), Neuroblastoma Research and Treatments (110 papers) and Sarcoma Diagnosis and Treatment (105 papers). Lawrence H. Einhorn is often cited by papers focused on Testicular diseases and treatments (330 papers), Neuroblastoma Research and Treatments (110 papers) and Sarcoma Diagnosis and Treatment (105 papers). Lawrence H. Einhorn collaborates with scholars based in United States, Canada and United Kingdom. Lawrence H. Einhorn's co-authors include Stephen D. Williams, John P. Donohue, Patrick J. Loehrer, Nasser H. Hanna, F. Anthony Greco, Robert Birch, Craig R. Nichols, Richard S. Foster, Mary J. Brames and Thomas M. Ulbright and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Lawrence H. Einhorn

532 papers receiving 26.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

1977 1.2k citations Lawrence H. Einhorn et al. profile →
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

1987 825 citations Stephen D. Williams, Lawrence H. Einhorn et al. profile →
Recommendations on the Use of ¹⁸F-FDG PET in Oncology

2008 790 citations Lawrence H. Einhorn et al. profile →
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

1992 752 citations Patrick J. Loehrer, Lawrence H. Einhorn et al. Journal of Clinical Oncology profile →
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 542 citations Lawrence H. Einhorn et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 500 citations Nasser H. Hanna, Lawrence H. Einhorn et al. Journal of Clinical Oncology profile →
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

2016 397 citations Lawrence H. Einhorn et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Lawrence H. Einhorn

Since Specialization

Citations

This map shows the geographic impact of Lawrence H. Einhorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence H. Einhorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence H. Einhorn more than expected).

Fields of papers citing papers by Lawrence H. Einhorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence H. Einhorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence H. Einhorn. The network helps show where Lawrence H. Einhorn may publish in the future.

Co-authorship network of co-authors of Lawrence H. Einhorn

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence H. Einhorn. A scholar is included among the top collaborators of Lawrence H. Einhorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence H. Einhorn. Lawrence H. Einhorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer 2025 ·JNCI Journal of the National Cancer Institute ·Sarah L. Kerns, Paul C. Dinh, Patrick O. Monahan, Timothy E. Stump, Chunkit Fung, Howard D. Sesso, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, (unknown), Christian Kollmannsberger, Neil E. Martin, Kathryn Nevel, John C. Kincaid, Lawrence H. Einhorn, Lois B. Travis	1
2	Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), John P. Sfakianos, George Laliotis, Clint Cary, Timothy A. Masterson, Samuel Rivero-Hinojosa, (unknown), (unknown), (unknown), Shivaram Cumarasamy, Jennifer King, (unknown), (unknown), Tanya B. Dorff, (unknown), Minetta C. Liu, Lawrence H. Einhorn, Alex Chehrazi‐Raffle, Nabil Adra	1
3	Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy 2023 ·Journal of Clinical Oncology ·Victoria A. Sanchez, Megan M. Shuey, Paul C. Dinh, Patrick O. Monahan, Sophie D. Fosså, Howard D. Sesso, M. Eileen Dolan, Lawrence H. Einhorn, David J. Vaughn, Neil E. Martin, Darren R. Feldman, Kurt Kroenke, Chunkit Fung, Robert D. Frisina, Lois B. Travis	23
4	Impact of pain and adverse health outcomes on long-term US testicular cancer survivors 2023 ·JNCI Journal of the National Cancer Institute ·Paul C. Dinh, Patrick O. Monahan, Sophie D. Fosså, Howard D. Sesso, Darren R. Feldman, M. Eileen Dolan, Kathryn Nevel, John C. Kincaid, David J. Vaughn, Neil E. Martin, Victoria A. Sanchez, Lawrence H. Einhorn, Robert D. Frisina, Chunkit Fung, Kurt Kroenke, Lois B. Travis	7
5	Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors 2023 ·Journal of Clinical Oncology ·Jennifer King, (unknown), Kenneth A. Kesler, (unknown), Sandra K. Althouse, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra	4
6	Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer 2022 ·Cancer Medicine ·(unknown), (unknown), Paul C. Dinh, Victoria A. Sanchez, Matthew R. Trendowski, Megan M. Shuey, (unknown), Darren R. Feldman, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Neil E. Martin, Lawrence H. Einhorn, Nancy J. Cox, Robert D. Frisina, Lois B. Travis, (unknown)	3
7	Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy 2022 ·Cancer Medicine ·(unknown), Matthew R. Trendowski, Emma Wilkinson, (unknown), Paul C. Dinh, Megan M. Shuey, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Robert Huddart, Neil E. Martin, Victoria A. Sanchez, Robert D. Frisina, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis, M. Eileen Dolan	11
8	Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor 2022 ·The Journal of Urology ·Jennifer King, Sandra K. Althouse, Clint Cary, Timothy A. Masterson, Richard S. Foster, (unknown), Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra	1
9	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors 2020 ·Clinical Cancer Research ·Matthew R. Trendowski, Heather E. Wheeler, (unknown), Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Lawrence H. Einhorn, Lois B. Travis, M. Eileen Dolan	9
10	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases 2017 ·The Oncologist ·Costantine Albany, Lawrence H. Einhorn, Lawrence Garbo, Thomas E. Boyd, Neil C. Josephson, Darren R. Feldman	40
11	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer 2017 ·Clinical Cancer Research ·M. Eileen Dolan, (unknown), Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshir‐Rouhani‐Fard, Patrick O. Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fosså, Daniel L. Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis	63
12	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy 2017 ·Publisher ·Chunkit Fung, Howard D. Sesso, AnnaLynn M. Williams, Sarah L. Kerns, Patrick O. Monahan, Mohammad Abu Zaid, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Christian Kollmannsberger, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir‐Rouhani‐Fard, (unknown), Lawrence H. Einhorn, Sophie D. Fosså, Lois B. Travis	1
13	Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients 2014 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Catherine E. Mosher, Joseph G. Winger, Nasser H. Hanna, Shadia I. Jalal, Achilles J. Fakiris, Lawrence H. Einhorn, Thomas J. Birdas, Kenneth A. Kesler, Victoria L. Champion	1
14	Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology 2011 ·Annals of Oncology ·Shadia I. Jalal, (unknown), A. Melnyk, Donald Richards, (unknown), M. Neubauer, Rafat Ansari, Ramaswamy Govindan, Daniel Bruetman, William B. Fisher, T. Breen, Cynthia S. Johnson, Menggang Yu, Lawrence H. Einhorn, Nasser H. Hanna	58
15	Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients With Disseminated Nonseminomatous Germ Cell Tumors: Is a Postchemotherapy Retroperitoneal Lymph Node Dissection Needed After Complete Remission? 2009 ·Journal of Clinical Oncology ·Yaron Ehrlich, Mary J. Brames, Stephen D.W. Beck, Richard S. Foster, Lawrence H. Einhorn	104
16	Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer 2000 ·American Journal of Clinical Oncology ·Guru Sonpavde, Rafat Ansari, Paul Walker, (unknown), (unknown), (unknown), René Gonin, Lawrence H. Einhorn	27
17	Ifosfamide in testicular cancer: the Indiana University experience. 1989 ·PubMed ·Patrick J. Loehrer, Stephen D. Williams, Lawrence H. Einhorn	10
18	Clinical stage I testis tumors: the medical oncologist's view. 1982 ·PubMed ·Stephen D. Williams, Lawrence H. Einhorn	8
19	Testicular tumors : management and treatment 1980 ·Lawrence H. Einhorn	8
20	Sequential combination chemotherapy for advanced, recurrent, squamous carcinoma of the head and neck 1976 ·Cancer Treatment Reviews ·R. B. Livingston, Lawrence H. Einhorn, M. A. Burgess, Jeffrey A. Gottlieb	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact